Companies work to develop combo mAb, NK cell COVID-19 therapy

By The Science Advisory Board staff writers

August 19, 2020 -- A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal antibody (mAb) and natural killer (NK) cells as a treatment for COVID-19. The efforts are spearheaded by Harbour BioMed and expand on the company's work in using mAb against SARS-CoV-2.

Additional collaborators include Utrecht University, Erasmus Medical Center, Viroclinics, and Kiadis Pharma. The collaboration will explore the synergies between mAb and NK cells in eliminating SARS-CoV-2 and virally infected cells.

The new product will utilize Kiadis' K-NK cell therapy platform to address the severe lack of functional NK cells in COVID-19 patients. K-NK-Id101 cells potentially have antiviral activity without exacerbating inflammation. The cells can be manufactured at a large scale and frozen down for storage, making global distribution easier.

The fully human, nonblocking antibody, 49F1, targets a conserved region of the SARS-CoV-2 spike protein and binds to both SARS-CoV-2 and SARS-CoV in vitro.

Novocellbio's COVID-19 cell therapy shows promising results
Novocellbio has confirmed that its autologous natural killer cell treatment agent is effective in killing SARS-CoV-2.
New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based...
ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...
Kleo, Green Cross collaborate on COVID-19 NK combination therapy
Kleo Pharmaceuticals is joining forces with Green Cross LabCell of South Korea to advance testing of natural killer (NK) cell therapies as a potential...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter